The main target of the Xiamen-based company is genetic testing for end consumers and clinics, targeting health internventions, drug development etc.
China Bio news release, October 26, 2016
Meigene completed 167 million RMB rounds of financing
The main target of the Xiamen-based company is genetic testing for end consumers and clinics, targeting health internventions, drug development etc.
China Bio news release, October 26, 2016